HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

human DNASE1 protein (dornase alfa)

Subscribe to New Research on human DNASE1 protein

a genetically engineered form of human enzyme is an orphan drug used for the treatment of cystic fibrosis as a mucolytic agent; RefSeq NM_005223

Also Known As:

dornase alfa; Pulmozyme; DNASE1 protein, human; Genentech brand of dornase alfa; Hoffmann-La Roche brand of dornase alfa; Roche brand of dornase alfa; deoxyribonuclease I, human; dornase alpha; recombinant human DNase; recombinant human deoxyribonuclease I; rhDNase

Networked: 270 relevant articles (53 outcomes, 75 trials/studies)

Relationship Network

Drug Context: Research Results

Enzymes and Coenzymes
- Enzymes: 34502
  - Hydrolases: 639
    - Esterases: 217
      - Deoxyribonucleases: 584
        Endodeoxyribonucleases
        Deoxyribonuclease I: 1017
        human DNASE1 protein: 270

Experts

1.	Ratjen, Felix: 6 articles (11/2015 - 03/2004)
2.	Tiddens, H A W M: 5 articles (05/2015 - 10/2007)
3.	Hop, Wim C J: 5 articles (08/2013 - 12/2003)
4.	Hop, W C J: 4 articles (02/2014 - 10/2007)
5.	Tiddens, Harm A W M: 4 articles (08/2013 - 12/2003)
6.	Wallis, C: 4 articles (01/2010 - 10/2001)
7.	Wallis, Colin: 4 articles (01/2010 - 08/2002)
8.	Bush, A: 4 articles (01/2010 - 10/2001)
9.	Metcalfe, C: 4 articles (01/2010 - 10/2001)
10.	Hodson, M E: 4 articles (10/2007 - 01/2001)

Related Diseases

1.	Cystic Fibrosis (Mucoviscidosis) 01/01/2001 - "Most respiratory complications in cystic fibrosis (CF) arise from abnormally viscid mucus, and rhDNase has shown to be effective in enhancing mucous clearance. " 08/01/1995 - "Treatment with either rhDNase or high-frequency oscillation has been shown to be effective in improving the physical and transport properties of airway secretions in cystic fibrosis (CF). " 12/01/2005 - "Nasally inhaled dornase alfa can be effective in patients with cystic fibrosis and sinonasal disease who do not respond to conventional therapy after surgical treatment. " 06/01/1999 - "Patients with cystic fibrosis (CF) receiving dornase-alfa had improved pulmonary function relative to a control group in a large randomized phase III controlled study. " 01/01/2011 - "Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial."
2.	Pulmonary Atelectasis 05/01/2009 - "Therapeutic effect of rhDNase is most effective in ameliorating atelectasis in the lungs within 10 doses. " 01/01/2009 - "In subgroup 1a, 16 patients had complete resolution of atelectases and minimal change in dystelectases after a treatment of 24 hours rhDNase, compared with the control group of 17 patients, who had 7 atelectases and 10 dystelectases at baseline and an improvement in only 1 out of 17 (6 %) patients after 24h. " 12/01/2012 - "There was no significant improvement in the chest X-ray atelectasis score in mechanically ventilated patients with new onset atelectasis who were nebulized with Dornase alpha twice a day. " 05/01/2009 - "rhDNase was effective in significantly improving established atelectasis without any major changes in gas exchange and ventilatory parameters. " 05/01/2009 - "rhDNase was more effective in improving chest radiographic atelectasis score in patients who had > moderate amounts of polymophonuclear neutrophils (P value = 0.0008), or bacteria (P value = 0.007) or both (P value = 0.004) present in their pre-rhDNase therapy trachea aspirate. "
3.	Lung Diseases (Lung Disease) 03/01/1995 - "Short-term (10-day) Phase I and II clinical trials showed dornase alfa to be safe and effective in improving pulmonary function in clinically stable CF patients with mild to moderate pulmonary disease (FVC > or = 40% of predicted value). " 07/01/1997 - "These in vitro results suggest that combined treatment with rhDNase and HS should be evaluated further as a potential mucotropic approach to augment the clearance of purulent sputum in CF lung disease." 04/01/1996 - "This article reviews the in vivo clinical studies conducted to determine the safety and efficacy of rhDNase in the treatment of pulmonary disease in CF. " 07/01/2015 - "Using existing data from three studies we assessed the sensitivity of moment ratios and abbreviated LCIs to (i) detect mild-to-moderate CF lung disease and (ii) detect treatment effects after 4 weeks of hypertonic saline or dornase alfa inhalation. " 03/01/2012 - "A 2-year, early intervention study of dornase alfa in CF patients with early lung disease demonstrated significant improvements in lung function and risk of exacerbation compared to placebo. "
4.	Inflammation 08/01/1998 - "The aim of this study was to determine whether airway inflammation would decrease after administration of rhDNase. " 03/01/2012 - "These encouraging results, possibly linked to indirect effects on inflammation, suggest a greater role for dornase alfa therapy in the early treatment of CF, where it may help preserve lung function and potentially extend survival." 03/15/2004 - "We conclude that in patients with CF, an increase in neutrophilic airway inflammation is found that is positively influenced by rhDNase treatment." 08/01/2002 - "In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF." 08/01/1998 - "Although the administration of rhDNase resulted in significant improvements in FEV1, there was no evidence of accompanying changes in airway inflammation."
5.	Cough 04/01/1996 - "A significant improvement in mucus cough transport was also induced by rhDNase from 25.5 mm with placebo to 27.0 mm with either 2 or 4 micrograms.mL-1 rhDNase. " 05/01/2001 - "There was improvement in the parents' assessments of the patients' well-being, with improvement in physical activity, decreased cough, sleep quality, and appetite in those subjects receiving rhDNase. " 01/01/1997 - "Thus the interaction of inhaled rhDNase with the purulent mucus and the endobronchial inflammatory processes may induce changes that result in rheological properties favoring clearance of sputum by cough." 02/01/1996 - "The calculated cough clearance index was also improved following treatment with rhDNase. " 01/01/2013 - "The mean change in daytime cough diary scores from baseline was also better in the placebo group compared to those on nebulized rhDNase, but the difference between groups was not statistically significant (MD 0.70; 95% CI -0.19 to 1.59). "

Related Drugs and Biologics

1.	human DNASE1 protein (dornase alfa)
2.	DNA (Deoxyribonucleic Acid)
3.	Deoxyribonucleases (DNase)
4.	Expectorants (Mucolytics)
5.	Mannitol (Osmitrol)
6.	Tissue Plasminogen Activator (Alteplase)
7.	Sodium Chloride (Saline Solution)
8.	Tobramycin (Nebcin)
9.	Anti-Bacterial Agents (Antibiotics)
10.	Enzymes

Related Therapies and Procedures

1.	Nebulizers and Vaporizers (Inhaler)
2.	Artificial Respiration (Mechanical Ventilation)
3.	Gamma Cameras (Gamma Camera)
4.	Chest Tubes (Chest Tube)
5.	Therapeutics